Cocaine Dependence Clinical Trial
Official title:
An fMRI Study of SYN115 in Cocaine Dependent Subjects
The dopamine system is critical in modulation of reward and has been implicated in the
initiation and maintenance of addiction (Volkow et al 2004). Medications that increase
dopamine either directly or indirectly have been shown to have preliminary efficacy at
reducing cocaine use in cocaine dependent subjects (Grabowski et al 2004a; Schmitz et al
2008). A novel class of medications that has recently been shown to indirectly modulate
dopamine function is adenosine A2A receptor antagonists (Fuxe et al 2007). Based on their
effect on dopamine function it has been suggested that these compounds may be efficacious in
the treatment of drug addiction (Ferre et al 2007c). Before clinical efficacy studies are
undertaken, more basic research on the effects of adenosine A2A antagonists on brain function
and behavior are warranted. The aim of this study is to examine the acute effects of a single
dose of the selective adenosine A2A antagonist (SYN115, Synosia Therapeutics, Chemical name:
4-Hydroxy-4-methyl-piperidine-1-carboxylic
acid-(4-methoxy-7-morpholin-4-yl-benzothiazol-2-yl)-amide) on brain function and behavior in
cocaine dependent individuals using functional magnetic resonance imaging (fMRI). To examine
the effect of a single dose of SYN115 on brain function and behavior in cocaine dependent
subjects.
Hypotheses:
1. SYN115 100 mg will increase brain activation in the dorsolateral prefrontal cortex
compared to placebo in cocaine dependent subjects performing a working memory task.
2. SYN115 100 mg will increase brain activation in the ventral striatum compared to placebo
in cocaine dependent subjects performing a reversal learning task.
3. SYN115 100 mg will reduce brain activation in the anterior cingulate gyrus and amygdala
compared to placebo in cocaine dependent subjects performing a cocaine-word Stroop task.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04994821 -
tDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study
|
Phase 2 | |
Completed |
NCT01402492 -
Cocaine Use Reduction With Buprenorphine
|
Phase 2/Phase 3 | |
Completed |
NCT01601743 -
Exercise as a Behavioral Treatment for Cocaine Dependence
|
N/A | |
Completed |
NCT01176591 -
HBPL Study of the Impact of the NK1 Antagonist Aprepitant
|
Phase 2 | |
Completed |
NCT00880997 -
The Efficacy of Doxazosin for Cocaine Users
|
Phase 1 | |
Completed |
NCT00566969 -
Cocaine Withdrawal and Pharmacotherapy Response
|
N/A | |
Completed |
NCT00585520 -
Sex Differences in Progesterone Effects on Responses to Stress and Drug Cues
|
Phase 1 | |
Completed |
NCT00368290 -
Modafinil Treatment for Cocaine Dependence and HIV High-Risk Behavior
|
Phase 2 | |
Completed |
NCT00322309 -
Efficacy of Mirtazapine in Depressed Cocaine Dependent Subjects
|
Phase 2 | |
Completed |
NCT00385801 -
Study of the Effects of Risperdal Consta on Brain Reward Circuitry Function, Craving and Cocaine Use in Active Cocaine Dependence
|
Phase 2 | |
Completed |
NCT00842517 -
Long Term Maintenance of Drug Abstinence
|
Phase 1 | |
Completed |
NCT00167245 -
Topiramate for Alcohol and Cocaine Dependence
|
Phase 2 | |
Not yet recruiting |
NCT05974202 -
rTMS and Cognitive-behavioral Therapy for Cocaine Use Disorder
|
Phase 2 | |
Completed |
NCT04411914 -
Pharmaco-Magnetic Resonance Spectroscopy (MRS) Study of Clavulanic Acid
|
Phase 1 | |
Active, not recruiting |
NCT03266939 -
Rebalancing the Serotonergic System in Cocaine Dependence
|
Phase 1 | |
Completed |
NCT02563769 -
Clavulanic Acid (CLAV) and Cocaine Interaction Safety Study
|
Phase 1 | |
Recruiting |
NCT06159387 -
Randomized, Double-blind, Placebo-controlled Cannabis Extract x Placebo for Cocaine Addicts
|
Phase 4 | |
Terminated |
NCT02935101 -
Effects of Glucocorticoids on Craving During Detoxification Treatment of Heroin and/or Stimulants
|
Phase 2 | |
Completed |
NCT02018263 -
Validation of a Remote Wireless Sensor Network (WSN) Approach to the Individualized Detection of Cocaine Use in Humans
|
Phase 1 | |
Withdrawn |
NCT01406522 -
Tacrine Effects on Cocaine Self-Administration and Pharmacokinetics
|
Phase 2 |